Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
1,314 results in Europe PMC
PubMed plus preprints and full-text open access papers. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Ravulizumab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial.
Barratt J, Farag YMK, Rice K, Cammett TJ, Inker LA, Trimarchi H, Bruchfeld A, Heerspink HJL, Liew A, Carroll K, Zhang H, Norouzi S, Hou S, Park S, Pérez Valdivia MÁ, Radhakrishnan J, Suzuki Y, Schneider B, Marsala J, Carrillo-Infante C, Lake SL, Singh AK, Nolan S, Lafayette RA, I CAN Trial Group. · N Engl J Med · 2026 · cited 0 timesclinical trial, phase iii, multicenter study
- Interim Analysis of a Phase 3 Trial of Povetacicept in IgA Nephropathy.
Barratt J, Zhang H, Han SH, Suzuki Y, Tumlin J, Chacko B, Noronha IL, Madan A, Duivenvoorden R, Azzi JR, Nester C, Dong C, Ahluwalia N, Li J, Bozic C, Egbuna O, Wong MG, Lafayette R, RAINIER AIS-D08 Trial Group. · N Engl J Med · 2026 · cited 1 timesclinical trial, phase iii, multicenter study
- Mapping the complement-targeted landscape in igA nephropathy: a systematic review with structured descriptive synthesis
Li X, Zhong C, Zhang L, Liu Y. · Front Med (Lausanne) · cited 0 timesOpen accesssystematic-review, review
- Associations of renal complement deposition with oxford MEST-C pathological lesions and renal outcomes in Iga nephropathy: a meta-analysis.
Bao Y, Xu J, Nan H, Liu M, Zhang S. · Front Immunol · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Mapping the complement-targeted landscape in igA nephropathy: a systematic review with structured descriptive synthesis.
Li XY, Zhong CY, Zhang LN, Liu Y. · Front Med (Lausanne) · 2026 · cited 0 timessystematic review
- Telitacicept for IgA nephropathy: a systematic review and meta-analysis of observational studies.
Zheng L, Gu X, Yang C, Zhang W, Fu C, Wang Y, Fang X. · Front Med (Lausanne) · 2026 · cited 0 timesOpen accesssystematic review, systematic-review
- The Impact of Renin-Angiotensin-Aldosterone System Inhibitors in IgA Nephropathy: A Meta-Analysis of Randomized Controlled Trials.
Rastogi A, Sarkar M, Kawai K, Munoz G, Simon L, Hwang M, Khalid M, Rhee CM. · Clin J Am Soc Nephrol · 2026 · cited 0 timesmeta-analysis
- Finerenone in IgA nephropathy: a systematic review and meta-analysis.
Wu J, Li Y, Luo L, Wu Q, Mou Y, Xu Y, Li Q, Ren Q, Qiao Y, Huang W. · BMC Nephrol · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Telitacicept for IgA Nephropathy - Interim Analysis of a Phase 3 Trial.
Lv J, Liu L, Wang W, Wang X, Zuraw Q, Perkovic V, Fang J, Zhang H, TELIGAN Investigators. · N Engl J Med · 2026 · cited 14 timesclinical trial, phase iii, multicenter study
- Mechanisms and management of IgA nephropathy progression to end-stage renal disease: From the "four-hit" theory to precision medicine.
Zhou T, Liu S, Zhang H, Ji Y, Lv W. · Clin Nephrol · 2026 · cited 0 timessystematic review
- Crystalline κ-light-chain proximal tubulopathy in Waldenström macroglobulinemia with an IgA nephropathy pattern: a case report and systematic review.
Zhang J, Chen X, Yao L, Li T, Sun X, Xu X, Bai P, Shao L, Pei J. · Front Immunol · 2026 · cited 0 timesOpen accessresearch support, non-u.s. gov't, systematic review
- Iptacopan in IgA Nephropathy - Final 24-Month Data.
Barratt J, Eren N, Kashihara N, Maes B, Rizk DV, Rovin B, Trimarchi H, Zhang H, Wang W, Kocyigit I, Hao C, Tesař V, Turgutalp K, Yang L, Xing G, Duro Garcia V, Han SH, Lu W, Pisani A, Weinmann-Menke J, Eitner F, Guerard N, Butylin D, Monaco L, Scosyrev E, Magirr A, Renfurm R, Hach T, Perkovic V, APPLAUSE-IgAN Study Group. · N Engl J Med · 2026 · cited 22 timesclinical trial, phase iii, multicenter study
- Tonsillectomy and immunosuppression improve outcomes in Caucasians with high-risk IgA nephropathy.
Kochoyan ZS, Dobronravov VA. · Nephrol Dial Transplant · 2026 · cited 0 timescontrolled clinical trial, comparative study
- Genetic Determinants of Steroid Responsiveness in IgA Nephropathy.
Xu LL, Zhou XJ, Zhou XJ, Bi W, Zhang P, Shi SF, Liu LJ, Lv JC, Zhang H. · J Am Soc Nephrol · 2026 · cited 3 timesrandomized controlled trial
- Humoral Response to COVID-19 Vaccines and Infection during Sibeprenlimab Treatment of IgA Nephropathy: Data from the ENVISION Trial.
McCafferty K, Barratt J, Suzuki Y, Liew A, Rizk DV, Chacko B, Kooienga L, Lafayette R, Wong MG, Pasetti MF, Shriver MC, Follman K, Moc Willeford C, Sahay M, Honig G, Andrews L, Olinski LE, Mathur M, Oldach D. · Clin J Am Soc Nephrol · 2026 · cited 1 timesOpen accessclinical trial, phase ii, multicenter study
- Risk Factors of Disease Progression in IgA Nephropathy: A Systematic Review and Meta-Analysis.
Xu D, Zhang M, Liang W, Fang L, Ge F. · Immun Inflamm Dis · 2026 · cited 2 timesOpen accessmeta-analysis, systematic review
- Crescents in native kidney biopsies from patients with IgA nephropathy and the risk of recurrence after kidney transplantation: a retrospective cohort study, systematic literature review and meta-analysis of observational studies.
Guzzo G, Al-Gobari M, Jaques C, Teta D, Pascual M, Herrera-Gomez F. · J Nephrol · 2026 · cited 0 timesmeta-analysis, systematic review
- Efficacy and safety of BAFF/APRIL-pathway inhibitors versus placebo in adults with IgA nephropathy: a systematic review with pairwise and network meta-analysis.
Mansour N, Elbarody RMF, Kamel AM. · BMC Nephrol · 2026 · cited 0 timesOpen accesssystematic review, network meta-analysis
- Efficacy and safety of budesonide for the treatment of IgA nephropathy: a systematic review and meta-analysis.
Nabi R, Ansab M, Hussain A, Ahmed HB, Rajpar NA, Abbasi SUAM, Lal PK, Ahmad O, Farooqi HA, Zahid T, Ahmed M, Nabi Z. · Int Urol Nephrol · 2026 · cited 0 timesmeta-analysis, systematic review
- APRIL-targeted and dual BAFF/APRIL blockade in primary IgA nephropathy: a systematic review and meta-analysis of randomized placebo-controlled trials.
Qu B, Zhu L, Ren Q, Wang B, Mao B. · Int Urol Nephrol · 2026 · cited 0 timesmeta-analysis, systematic review
- Diagnostic value of urinary exosomes in patients with IgA nephropathy and diabetic kidney disease: a systematic review and meta-analysis.
Xu R, Jiang L. · Front Med (Lausanne) · 2026 · cited 0 timesOpen accesssystematic review, systematic-review
- Targeted-release Budesonide (Nefecon) versus systemic glucocorticoids for IgA nephropathy: a placebo-anchored indirect treatment comparison of randomized controlled trials.
Qing J, Wei W, Wu J. · BMC Nephrol · 2026 · cited 0 timesOpen accessmeta-analysis, comparative study
- Efficacy and safety of sibeprenlimab in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials.
Tian Z, Li Y. · BMC Nephrol · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy.
Lafayette R, Barbour SJ, Brenner RM, Campbell KN, Doan T, Eren N, Floege J, Jha V, Kim BS, Liew A, Maes B, Pal A, Pecoits-Filho R, Phoon RKS, Rizk DV, Suzuki H, Tesař V, Trimarchi H, Wei X, Zhang H, Barratt J, ORIGIN Phase 3 Trial Investigators. · N Engl J Med · 2026 · cited 64 timesclinical trial, phase iii, multicenter study
- Efficacy of SGLT2 inhibitors in preventing end-stage kidney disease in patients with IgA nephropathy: a scoping review.
Phongphithakchai A, Klangbud WK, Srithongkul T, Raksasuk S, Chatatikun M. · Front Med (Lausanne) · 2026 · cited 0 timesOpen accesssystematic review, systematic-review
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.